Allergan and Molecular Partners has announced two-year data from their clinical studies of Abicipar in patients with wet age-related macular degeneration (AMD). In the second year of the studies, four injections of Abicipar given 12 weeks apart resulted in maintenance of visual gains comparable to monthly ranibizumab.
“We are pleased to see a sustained response at two-years with less frequent dosing of Abicipar compared to standard of care therapy,” said Patrick Amstutz, PhD, CEO of Molecular Partners. The data was presented at the Annual Meeting of the American Academy of Ophthalmology (AAO).
The U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) are currently reviewing regulatory applications for Abicipar in patients with wet AMD. Both agencies are expected to take action in 2020.
For descriptions of this and other anti-VEGF treatments for wet AMD now in clinical use and in trials, see Antiangiogenic Drugs Are Stopping Neovascularization in Wet Macular Degeneration
SOURCE: Press release